KemPharm uses its LAT
platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.
KMPH (Common Stock)
10/16/17 3:59 p.m. ET
KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD
KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate
KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.
View Attributions and Sources